A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712 | Terminated Phase 4 Results DMC

• 2 other identifiers: STU8789 0811-007CNV0042139
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open label, single-center, randomized phase IV pilot study of steroid and calcineurin inhibitor avoidance in renal transplant recipients. All patients will receive two doses of alemtuzumab to achieve peripheral T-cell depletion. Intravenous glucocorticoids will be administered prior to alemtuzumab administration to limit cytokine release syndrome in association with this monoclonal antibody, and continued for the first two days post-transplant. Thereafter, steroids will not be used for immunosuppression. All transplant recipients will be started on oral immunosuppressive therapy with mycophenolate mofetil (MMF) prior to transplant. Pretransplant, these patients will be randomized to receive, in addition, either tacrolimus (Tac) or sirolimus. After six months, patients in the tacrolimus arm who do not experience rejection will be randomized to continue on tacrolimus or to be converted to the combination of sirolimus and MMF. Individuals in this arm of the study who do not experience acute rejection, and demonstrate evidence of donor specific hyporesponsiveness at 9 months post-transplant (those staying on Tac + MMF) or 3 months post-conversion (those converted from Tac + MMF to sirolimus + MMF) will be weaned to MMF monotherapy. Individuals in the sirolimus + MMF arm who do not experience acute rejection and demonstrate evidence of donor specific hyporesponsiveness at 6 months post-transplant will be weaned to MMF monotherapy.

Conditions

Kidney Transplant Failure and Rejection

Keywords

Kidney Transplant; Living Donor Kidney Transplant Recipients

Outcome Measures

Primary Outcomes (1)

• The Incidence of Biopsy-proven Acute Allograft Rejection During the First 12 Months of Transplant.

  The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant.

  Within 12 months post kidney transplant

Secondary Outcomes (4)

• Severity of Acute Rejection During the First 6 and 12 Months Post-transplant

  Months 6-12 post-transplant

• Renal Function at 12 Months Post-transplant

  At 12 months post-transplant

• Incidence of Donor Specific Hyporesponsiveness Allowing for the Conversion to Monotherapy

  At 6 & 9 months post-transplant

• Patient and Graft Survival Rates at 6 and 12 Months Post-transplant

  At 6 & 12 months post-transplant

Study Arms (2)

Group 1: Alemtuzumab + TAC + MMF

ACTIVE COMPARATOR

Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.

Drug: Tacrolimus (TAC); Drug: Alemtuzumab; Drug: Mycophenolate mofetil (MMF)

Group 2: Alemtuzumab + Sirolimus + MMF

ACTIVE COMPARATOR

Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor. If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil.

Drug: Sirolimus; Drug: Alemtuzumab; Drug: Mycophenolate mofetil (MMF)

Interventions

Tacrolimus (TAC) DRUG

Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.

Also known as: Prograf®, FK506

Group 1: Alemtuzumab + TAC + MMF

Sirolimus DRUG

Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.

Also known as: Rapamune®, Rapamycin

Group 2: Alemtuzumab + Sirolimus + MMF

Alemtuzumab DRUG

Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.

Also known as: Campath®, Campath-1H, Mabcampath®

Group 1: Alemtuzumab + TAC + MMF; Group 2: Alemtuzumab + Sirolimus + MMF

Mycophenolate mofetil (MMF) DRUG

MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.

Also known as: Cellcept®

Group 1: Alemtuzumab + TAC + MMF; Group 2: Alemtuzumab + Sirolimus + MMF

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who are male or female age 18-65 years
• Donor age 18-65 years
• Patients who are single-organ recipients (kidney only)
• Women who are of childbearing potential must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of contraception throughout the treatment period.
• Subject (recipient) is able to understand the consent form and give written informed consent

You may not qualify if:

• Known sensitivity or contraindication to sirolimus, tacrolimus or MMF
• Patient with significant or active infection
• Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum
• Patients with PRA \> 20%
• Patients who are pregnant or nursing mothers
• Patients whose life expectancy is severely limited by diseases other than renal disease
• Ongoing active substance abuse, drug or alcohol
• Major ongoing psychiatric illness or recent history of noncompliance
• Significant cardiovascular disease (e.g.):
• Significant non-correctable coronary artery disease
• Ejection fraction below 30%
• History of recent myocardial infarction
• Malignancy within 3 years, excluding non-melanoma skin cancers
• Serologic evidence of infection with HIV or HBVsAg positive
• Patients with a screening/baseline total white blood cell count \< 4,000/mm3; platelet count \< 100,000/mm3; triglycerides \> 400 mg/dl; total cholesterol \> 300 mg/dl

Sponsors & Collaborators

• Northwestern University: lead
• Roche Pharma AG: collaborator

Study Sites (1)

Northwestern University/Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States

Location

Related Publications (24)

• Eggers PW. Effect of transplantation on the Medicare end-stage renal disease program. N Engl J Med. 1988 Jan 28;318(4):223-9. doi: 10.1056/NEJM198801283180406.

  PMID: 3275896 BACKGROUND

• Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000 Mar 2;342(9):605-12. doi: 10.1056/NEJM200003023420901.

  PMID: 10699159 BACKGROUND

• Barry JM. Immunosuppressive drugs in renal transplantation. A review of the regimens. Drugs. 1992 Oct;44(4):554-66. doi: 10.2165/00003495-199244040-00003.

  PMID: 1281071 BACKGROUND

• Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994 Aug 11;331(6):365-76. doi: 10.1056/NEJM199408113310606. No abstract available.

  PMID: 7832839 BACKGROUND

• Helderman JH, Van Buren DH, Amend WJ Jr, Pirsch JD. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol. 1994 Feb;4(8 Suppl):S2-9. doi: 10.1681/ASN.V48s2.

  PMID: 8193291 BACKGROUND

• Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis. 2001 Dec;38(6 Suppl 6):S25-35. doi: 10.1053/ajkd.2001.28923.

  PMID: 11729003 BACKGROUND

• Pirsch JD, D'Alessandro AM, Sollinger HW, Knechtle SJ, Reed A, Kalayoglu M, Belzer FO. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S238-42. doi: 10.1681/ASN.V212s238.

  PMID: 1498281 BACKGROUND

• Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996 Aug;42(8 Pt 2):1316-21.

  PMID: 8697605 BACKGROUND

• Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997 May-Jun;10(3):136-45.

  PMID: 9238621 BACKGROUND

• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998 Jun 11;338(24):1741-51. doi: 10.1056/NEJM199806113382407. No abstract available.

  PMID: 9624195 BACKGROUND

• DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol. 1998 Aug;25(4):492-502.

  PMID: 9728599 BACKGROUND

• Sia IG, Paya CV. Infectious complications following renal transplantation. Surg Clin North Am. 1998 Feb;78(1):95-112. doi: 10.1016/s0039-6109(05)70637-x.

  PMID: 9531938 BACKGROUND

• Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15;63(7):977-83. doi: 10.1097/00007890-199704150-00013.

  PMID: 9112351 BACKGROUND

• Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation. 1999 Dec 27;68(12):1865-74. doi: 10.1097/00007890-199912270-00009.

  PMID: 10628766 BACKGROUND

• Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001 May 15;71(9):1282-7. doi: 10.1097/00007890-200105150-00017.

  PMID: 11397963 BACKGROUND

• Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol. 1993 Jan;17(1):60-8. doi: 10.1097/00000478-199301000-00007.

  PMID: 7680544 BACKGROUND

• Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation. 1998 Nov 15;66(9):1207-10. doi: 10.1097/00007890-199811150-00016.

  PMID: 9825819 BACKGROUND

• Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998 Jun 6;351(9117):1701-2. doi: 10.1016/S0140-6736(05)77739-4. No abstract available.

  PMID: 9734890 BACKGROUND

• Calne RY. Initial Experience with Campath-1H in Renal Transplantation. Transplantation Reviews 2003, in press.

  BACKGROUND

• Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawy MM, Hu H, Bloom DD, Sollinger HW. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003 Jun;3(6):722-30. doi: 10.1034/j.1600-6143.2003.00120.x.

  PMID: 12780564 BACKGROUND

• Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15;76(1):120-9. doi: 10.1097/01.TP.0000071362.99021.D9.

  PMID: 12865797 BACKGROUND

• Hricik DE, Rodriguez V, Riley J, Bryan K, Tary-Lehmann M, Greenspan N, Dejelo C, Schulak JA, Heeger PS. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant. 2003 Jul;3(7):878-84. doi: 10.1034/j.1600-6143.2003.00132.x.

  PMID: 12814480 BACKGROUND

• Gebauer BS, Hricik DE, Atallah A, Bryan K, Riley J, Tary-Lehmann M, Greenspan NS, Dejelo C, Boehm BO, Hering BJ, Heeger PS. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant. 2002 Oct;2(9):857-66. doi: 10.1034/j.1600-6143.2002.20908.x.

  PMID: 12392292 BACKGROUND

• Reinsmoen NL. Cellular methods used to evaluate the immune response in transplantation. Tissue Antigens. 2002 Apr;59(4):241-50. doi: 10.1034/j.1399-0039.2002.590401.x.

  PMID: 12135422 BACKGROUND

MeSH Terms

Conditions

Rejection, Psychology

Interventions

Tacrolimus; Sirolimus; Alemtuzumab; Mycophenolic Acid

Condition Hierarchy (Ancestors)

Social Behavior; Behavior

Intervention Hierarchy (Ancestors)

Macrolides; Lactones; Organic Chemicals; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Caproates; Acids, Acyclic; Carboxylic Acids; Fatty Acids; Lipids

Results Point of Contact

• Title: Joseph Leventhal, MD, PhD, Associate Professor
• Organization: Comprehensive Transplant Center, Northwestern University

jleventh@nmh.org

(312) 695-1703

Study Officials

• Joseph R Leventhal, MD, PhD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: September 9, 2005
• First Posted: September 14, 2005
• Study Start: April 1, 2005
• Primary Completion: April 1, 2010
• Study Completion: April 1, 2010
• Last Updated: October 26, 2015
• Results First Posted: January 15, 2015

Record last verified: 2015-10

Locations

US (1)